期刊文献+

前列腺特异性抗原在前列腺癌诊断中的价值

THE DIAGNOSIS VALUE OF PSA FOR PROSTATE CANCER
原文传递
导出
摘要 目的探讨血清游离前列腺特异性抗原(fPSA)、血清总前列腺特异性抗原(tPSA)以及f/tPSA比值在前列腺癌确定诊断中的价值。方法选取2013年1月—2016年12月共701例该院行前列腺系统性穿刺活检或经尿道前列腺电切术患者的血清fPSA、tPSA并计算f/tPSA。结果前列腺癌组患者的fPSA、tPSA明显高于前列腺增生组(P<0.05),而f/tPSA低于前列腺增生组(P<0.05)。当tPSA在4~10ng/ml范围之内时,前列腺癌组与前列腺增生组患者的tPSA的差异均无统计学意义(P>0.05),但f/tPSA差异有统计学意义(P<0.05),前列腺癌组明显低于前列腺增生组。结论联合检测血清fPSA、tPSA以及f/tPSA比值明显优于单纯检测tPSA,在前列腺癌的诊断中具有重要的价值。 Objective To study the value of serum free prostate specific antigen( fPSA) ,total prostate spe- cific antigen(tPSA) ,fPSA to tPSA ratio in the diagnosis of prostate cancer. Methods A total of 701 pa- tients of prostatic diseases, who underwent prostate biopsy or transurethral resection of the prostate in au- thor's hospital from Jan 2013 to Dec 2016, were selected into the study. These patients" fPSA, tPSA, fPSA to tPSA ratio were all calculated. Results Serum fPSA and tPSA in prostate cancer(Pca) group were sig- nificantly higher than that in benign prostatic hyperplasia( BPH) group (P〈0.05). When it was between 4 -10ng/ml, tPSA in Pca group had no significant difference with that in BPH group (P〉0.05}. While,the ratio of fPSA to tPSA in Pca group was significantly lower than that in BPH group(P〈0.05). Conclusion Combining the detection of fPSA, tPSA and fPSA to tPSA ratio is much better than detecting tPSA alone and plays an important role in the diagnosis of prostate cancer.
出处 《中国煤炭工业医学杂志》 2017年第4期369-371,共3页 Chinese Journal of Coal Industry Medicine
基金 河北省2016年度医学科学研究重点课题项目(编号:20160846)
关键词 前列腺癌 TPSA FPSA F/TPSA 诊断 Prostate cancer tPSA fPSA fPSA to tPSA ratio Diagnosis
  • 相关文献

参考文献4

二级参考文献47

  • 1赫杰,赵平,陈万青.2011中国肿瘤登记年报[M].北京:军事医学科学出版社,2012:2-5,26 -37,74 -75.
  • 2Segi M. Cancer mortality for selected sites in 24 countries(1950-57 ) [ M ]. Japan : Department of Public Health,Tohoku Univer-sity of Medicine, 1960.
  • 3FerlayJ, Shin HR, Bray F, et al. Estimates of worldwide burdenof cancer in 2008 : GLOBOCAN 2008 [ J]. Int J Cancer, 2010,127(12) : 2893 -2917.
  • 4Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin’2011,61(2) :69 -90.
  • 5Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [ J].CA Cancer J Clin,2012,62( 1) :10 - 29.
  • 6Jemal A, Bray F, Center M M, et al, Global cancer statistics [J]. CA Cancer J Clin, 2011 , 61 (2) : 69 - 90.
  • 7Crawford E D. Epidemiology of prostate cancer[J]. Urology, 2003, 62(6 Suppl 1) , 3 -12.
  • 8Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence, and mortality. Part I: international comparisons [J]. BJU Int, 2002, 90 ( 2) : 162 - 173.
  • 9Gronberg H. Prostate cancer epidemiology [J]. Lancet, 2003, 361 (9360) : 859 - 864.
  • 10Jemal A, Siegel R, Xu J, et al. Cancer statistics 2010 [J]. CA Cancer J Clin, 2010, 60(5): 277 -300.

共引文献803

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部